Gyre Therapeutics, Inc. (GYRE): who owns it and who trades it
As of Nov 16, 2026, GYRE insiders reported 18 open-market sales worth $953K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Weiguo Ye (Chief Operating Officer), with $870K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling GYRE Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GYRE
59 funds and institutions reported GYRE shares worth $58.3M at the end of Q2 2026, about 9% of the company. The largest holder is HSG Holding Ltd with 3.9%.
Funds and institutions (13F) 9%Everyone else 91%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| HSG Holding Ltd | 3.75M | 3.87% | $24.7M | New |
| BlackRock, Inc. | 993,943 | 1.03% | $6.6M | +31% |
| Octagon Capital Advisors LP | 954,416 | 0.98% | $6.3M | New |
| Vanguard Capital Management LLC | 876,927 | 0.90% | $5.8M | -11% |
| Geode Capital Management, LLC | 532,950 | 0.55% | $3.5M | +24% |
| State Street Corp | 245,402 | 0.25% | $1.6M | +13% |
| Charles Schwab Investment Management Inc | 184,286 | 0.19% | $1.2M | +12% |
| Sixth Street Partners Management Company, L.P. | 184,286 | 0.19% | $1.2M | New |
| Northern Trust Corp | 169,537 | 0.17% | $1.1M | +27% |
| SBI Securities Co., Ltd. | 166,750 | 0.17% | $1.1M | -2% |
| Vanguard Fiduciary Trust Co | 151,073 | 0.16% | $996K | +10% |
| Vanguard Portfolio Management LLC | 123,953 | 0.13% | $817K | +78% |
| Goldman Sachs Group Inc | 86,235 | 0.09% | $568K | +18% |
| Bank of New York Mellon Corp | 62,750 | 0.06% | $414K | +45% |
| Morgan Stanley | 41,691 | 0.04% | $275K | +382% |
| Strs Ohio | 25,800 | 0.03% | $170K | +22% |
| Dimensional Fund Advisors LP | 25,268 | 0.03% | $167K | No change |
| Alliancebernstein L.P. | 24,590 | 0.03% | $171K | +13% |
| Nuveen, LLC | 24,505 | 0.03% | $161K | New |
| UBS Group AG | 18,763 | 0.02% | $124K | -11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GYRE insiders reported $0 of open-market purchases and $953K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 3,000 | $6.35 | $19.1K | Form 4 |
| Jun 11, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 2,800 | $6.17 | $17.3K | Form 4 |
| Jun 10, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 5,000 | $6.24 | $31.2K | Form 4 |
| Jun 10, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 6,418 | $6.21 | $39.9K | Form 4 |
| Jun 9, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 3,000 | $6.15 | $18.4K | Form 4 |
| Jun 9, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 14,500 | $6.14 | $89K | Form 4 |
| Jun 5, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 15,401 | $6.40 | $98.6K | Form 4 |
| Jun 4, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 19,575 | $6.13 | $120K | Form 4 |
| May 26, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 4,000 | $6.10 | $24.4K | Form 4 |
| May 22, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 3,500 | $6.08 | $21.3K | Form 4 |
| May 21, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 12,820 | $6.15 | $78.8K | Form 4 |
| May 20, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 9,400 | $6.15 | $57.8K | Form 4 |
| May 19, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 9,120 | $6.37 | $58.1K | Form 4 |
| May 18, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 200 | $6.62 | $1.3K | Form 4 |
| May 15, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 13,100 | $6.65 | $87.1K | Form 4 |
| May 14, 2026 | Weiguo Ye | Chief Operating Officer | Sale | 15,580 | $6.91 | $108K | Form 4 |
| May 6, 2026 | Ying Luo | CEO | Sale | 10,136 | $8.04 | $81.5K | Form 4 |
| May 5, 2026 | Ying Luo | CEO | Sale | 179 | $8.01 | $1.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Weiguo Ye | Chief Operating Officer | – | $870K | Jun 18, 2026 |
| Ying Luo | Chief Executive Officer, Director | – | $82.9K | May 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GYRE short interest
Low short interest. 2.0% of GYRE shares are sold short: about 1 share in 50. Over the last 12 reports the number of shares short went up 34%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.24M GYRE shares were sold short, 2.0% of the shares outstanding, up 16.3% from the report before. At the average daily volume of 157,556 shares, buying them all back would take about 14.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.24M | 2.01% | +16% | 157,556 | 14.2 |
| Oct 15, 2026 | 1.93M | 1.73% | +0% | 118,301 | 16.3 |
| Sep 30, 2026 | 1.92M | 1.72% | +11% | 277,117 | 6.9 |
| Sep 15, 2026 | 1.73M | 1.55% | +1% | 90,007 | 19.2 |
| Aug 31, 2026 | 1.71M | 1.53% | -2% | 49,644 | 34.4 |
| Aug 14, 2026 | 1.75M | 1.57% | -4% | 56,232 | 31.1 |
| Jul 31, 2026 | 1.82M | 1.88% | -11% | 48,780 | 37.4 |
| Jul 15, 2026 | 2.04M | 2.11% | +12% | 84,482 | 24.2 |
| Jun 30, 2026 | 1.83M | 1.88% | +5% | 155,116 | 11.8 |
| Jun 15, 2026 | 1.74M | 1.79% | +4% | 94,410 | 18.4 |
| May 29, 2026 | 1.67M | 1.72% | -0% | 94,813 | 17.6 |
| May 15, 2026 | 1.68M | 1.73% | +6% | 92,210 | 18.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
GYRE Therapeutics company events
GYRE Therapeutics filed 19 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 22, 2026LeadershipGyre Therapeutics, Inc. entered into an employment agreement with Ying Luo, Ph.D., to continue to serve as Gyre’s Chief Executive Officer. Filing
- Sep 1, 2026AnnouncementShared information with investors. Filing
- Aug 26, 2026AnnouncementShared information with investors. Filing
- Aug 7, 2026ResultsReleased financial results. Filing
- Jul 16, 2026LeadershipThe board of directors of Gyre Therapeutics, Inc. appointed Yue Xiong, Ph.D. as a Class I director of the Company, Maxwell Kirkby as a Class II director of the Company and Claire Weston, Ph.D. as a Class III director of the Company, in each case effective as of August 1, 2026. Filing
- Jul 15, 2026ResultsAmended an earlier report. Released financial results. Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- Jun 2, 2026AnnouncementShared information with investors. Filing
- May 14, 2026AnnouncementShared information with investors. Filing
- May 12, 2026AnnouncementShared information with investors. Filing
- May 7, 2026ResultsReleased financial results. Filing
- May 4, 2026LeadershipResignation of Directors In accordance with the Merger Agreement, immediately prior to the Effective Time, Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his… Filing
- Apr 17, 2026AgreementAmended an earlier report. Of the Original Form 8-K solely to correct the clerical error. Filing
- Mar 23, 2026AnnouncementGyre Pharmaceuticals Co., Ltd., Gyre Therapeutics, Inc.’s majority indirectly owned subsidiary, submitted its New Drug Application to the Center for Drug Evaluation of China’s National Medical Products Administration for F351 (Hydronidone), the Company’s lead product candidate, for the treatment of… Filing
- Mar 12, 2026AnnouncementShared information with investors. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 2, 2026LeadershipResignation of Directors In accordance with the Merger Agreement, immediately prior to the Effective Time, Thomas Eastling and Songjiang Ma will resign from the Board and any respective committee of the Board to which they were members, and Mr. Ma will also resign from his position as President of… Filing
- Jan 5, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
GYRE Therapeutics financials
Famous investors that hold GYRE
1 of the 50 well-known investors we track reported holding GYRE in their latest 13F filing. The largest position is Israel Englander's, worth $148K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 20,136 | $148K | 0.0% | +9% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Gyre Therapeutics, Inc. (GYRE) stock
Who owns the most GYRE stock?
The largest reported owner of Gyre Therapeutics, Inc. (GYRE) is HSG Holding Ltd, with 3.9% of the company. In total, 59 funds and institutions reported holding GYRE at the end of Q2 2026, together about 9% of the shares. See the largest owners.
Are GYRE insiders buying or selling?
In the last 12 months, GYRE insiders reported no open-market purchases and 18 sales worth $953K. The latest trade was on Jun 18, 2026. See every trade.
What is the short interest in GYRE?
As of Oct 30, 2026, 2.24M GYRE shares were sold short, 2.0% of the shares outstanding, up 16.3% from the report before. At the average daily volume of 157,556 shares, buying them all back would take about 14.2 trading days (days to cover). See the history.
Which famous investors hold GYRE?
1 of the 50 well-known investors we track reported GYRE in their latest 13F filing, including Israel Englander. The largest position is worth $148K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.